Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.
However, the company's high debt load is a concern. Kisqali, Pluvicto Drive Novartis (NVS) Amid Competition Per the Zacks analyst, drugs like Entresto, Kesimpta, Pluvicto, Kisqali and Leqvio continue ...
NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...
In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...
Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43% cc), Kesimpta (+28% cc), Pluvicto (+50% cc) and Leqvio (+119% cc)Core operating ...
Justin Welby, the leader of 85 million Anglicans worldwide, announced his resignation days after a report found he had taken insufficient action over claims of abuse. By Stephen Castle and Mark ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Melania Trump declined Jill Biden's invitation for tea at the White House as their husbands meet for the customary post-election lunch. Melania reportedly cited a scheduling conflict but sources ...
Justin Welby, the leader of 85 million Anglicans worldwide, announced his resignation days after a report found he had taken insufficient action over claims of abuse. By Stephen Castle and Mark ...
Nov. 11, 2024 — Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell ...